Biological drugs account for 65%, Chinese medicine is not "lying flat", A-share listed pharmaceutical companies invest the most in these products!

In recent years, driven by a series of pharmaceutical reforms and national scientific and technological innovation strategies, the research and development of innovative drugs is in full swing, and the investment in research and development has increased
year by year.

Previous article (A-share pharmaceutical companies R&D investment TOP100 released!) 14 companies over 1 billion, 90% of pharmaceutical companies have increased R&D investment, Baekje, Hengrui, Fosun.

Although many companies do not disclose the amount of R&D investment in specific projects in their annual reports, they can still see the R&D investment of the disclosed projects and know a little about the trend of new drug R&D
.

These ten new drugs have the most investment in research and development

According to the statistics of the product research and development detailed database of listed enterprises of Pharmaceutical Intelligence, the cumulative R&D investment of these 10 projects is the largest:

Data source: product research and development detailed database of listed enterprises of Pharmaceutical Intelligence, announcements of various enterprises

The first place is Junshi Bio's JS001 (terreprimumab), which has invested a total of 3.

Triprilizumab is a recombinant humanized anti-PD-1 monoclonal antibody injection, which is the first domestic PD-1 monoclonal antibody drug
successfully marketed in China.

As the first approved domestic PD-1 monoclonal antibody, Triprilizumab has always been the main source of income and profit of
Junshi Bio.

Recently, Junshi also issued the "2022 Specific Target Issuance A-share Stock Prospectus (Review Draft)", which shows that JS001 and JS001 and other related new drug combination drug research and development projects involve a total of 2.

Carellil lizumab and terreprimab are both PD-1 monoclonal antibodies, as of the end of 2019, Hengrui annual report disclosed a cumulative R&D investment of 740 million yuan, according to the latest announcement of Hengrui Pharmaceutical, the current Carellil lizumab related projects have invested more than 2 billion yuan, which shows that major pharmaceutical companies attach importance to
PD-1 products.

In the field of anti-oncology, another innovative drug of Hengrui, pyrrolitinib, is also expensive
.
As of the end of 2019, the cumulative R&D investment in pyrrotinib-related projects was about 740 million yuan, and according to the data disclosed by Hengrui in June this year, the cumulative investment has exceeded 1 billion yuan
.

In addition to the field of oncology, the new crown pneumonia vaccine is also a key area for pharmaceutical companies to invest in
the past two years.
Among them, CanSino's Ad5-nCoV new crown vaccine has invested a total of 855 million yuan
by 2021.

In fact, since the outbreak of the new crown epidemic in early 2020, CanSino has focused on the
COVID-19 vaccine.
Its adenovirus vector COVID-19 vaccine Ad5-nCoV (trade name "Kevisa") was approved for conditional marketing in Chinese mainland in February 2021 and subsequently expanded to overseas markets
.
In 2021, CanSino Bio achieved revenue of 4.
3 billion yuan and net profit attributable to the mother of 1.
914 billion yuan, turning a loss into a profit
for the first time.
At the same time, CanSino has also made a leap
from biotech to biopharma.

Biological drugs account for 65%, and the research and development of traditional Chinese medicines has not been "lying flat"

According to the statistics of drug types, among these 100 products (projects), biological products account for more than half, accounting for 65%, and chemical drugs and traditional Chinese medicines account for 23% and 12%
respectively.

Since the 20th century, with the gradual deepening of people's understanding of genetics, life evolution and biology, biotechnology has continued to make breakthroughs, and the biopharmaceutical industry has entered a stage of
rapid development.
In 2012, AbbVie's adalimumab "Humira" topped the global sales championship with $9.
48 billion, and the rising new generation of drug king Keytruda is also a monoclonal antibody, all of which show the great potential
of biological drugs.

In China, before 2015, there was less research and development for biological drugs, and most of them were based on recombinant proteins and vaccines
.

However, after 2015, with the introduction of a series of new drug policies, the influx of overseas capital and the return of a large number of medical talents, domestic biopharmaceutical research and development ushered in a period of
vigorous development.
Whether it is a new rise in biopharmaceutical companies or traditional large pharmaceutical companies have joined the research and development of biological drugs, monoclonal antibodies, double antibodies, ADC, CAR-T and other fields are hot
.

On the other hand, it is worth noting that the research and development of traditional Chinese medicine and going to sea have never stopped, but the progress has been slow, until the past two years, it has only slightly improved
.

As early as 1998, Tasly had planned to market
compound danshen drop pills in the United States.
In 1998, compound danshen drops were officially applied for by the U.
S.
Food and Drug Administration (FDA) for the first clinical study (IND) as a drug, and in 2006 it was again approved by the FDA for IND, identifying clinical indications for the prevention and treatment of chronic stable angina, but it has not yet been approved
.

According to Tasly's 2018 annual report, the cumulative R&D investment in the FDA project of compound danshen drop pills has reached 480 million yuan
.
Phase 3 clinical trials of compound danshen drops for the treatment of angina and acute altitude sickness indications are still ongoing, and it will take time to answer
whether it can successfully go to sea.

The progress of innovative Chinese medicine drugs in China is also slow, and few new drugs are approved every year
.

Fortunately, in the past two years, the innovative drugs of traditional Chinese medicine have finally improved
.

According to the statistics of Yaozhi Data, there are a total of 10 new Chinese medicine drugs approved for listing in 2021, 9 of which are Chinese medicine compounds (8 are clinical experience formulas of traditional Chinese medicine, 1 basic prescription of hospital preparations), and 1 effective part
of traditional Chinese medicine.
There were only 3 new Chinese medicine drugs approved in 2020, and even fewer
before that.

The rise of these new brands and new categories that adapt to the new era shows that the road to the research and development of new Chinese medicine drugs has been opened, and the research and development of Chinese medicines has also ushered in a new upsurge
.

Schedule: A-share listed pharmaceutical companies invest in product research and development TOP100

Note: The cumulative R&D investment of pharmaceutical (product) products/research projects only counts the data disclosed in the annual report, if there is any error or omission, please correct it
.

Data source: product research and development detailed database of listed enterprises of Pharmaceutical Intelligence, announcements of various enterprises